‘While that is disappointing for the Alzheimer’s community, there have been many doubts expressed about Dimebon. These doubts have been documented by leading researchers, including ex-National Institutes of Health staffers. This failure of Dimebon, that was hypothesized to act as a mitochondrial pore blocker, along with the repeated failures of every medication studied for eliminating beta amyloid from the brain as a way to manage Alzheimer’s disease, shows that novel mechanisms of actions that attempt to modify the condition itself, than treat symptoms rather, are necessary,’ said Cameron Durrant, MD, MBA, Executive Chairman of the ANAVEX Plank of Directors. ANAVEX can be getting ready to enter Phase 1 scientific trials with ANAVEX 2-73, its lead substance for the treating Alzheimer’s disease, this year later.The results showed that immune cells are more vigorous in the brains of people with schizophrenia and those at risk for the disease. ‘Our findings are particularly exciting since it was previously unknown whether these cells become energetic before or after onset of the condition,’ lead author Peter Bloomfield, of the Medical Study Council’s Clinical Sciences Center at Imperial University London, said in a college news release. ‘We now have shown this early involvement, mechanisms of the condition and new medications may hopefully be uncovered,’ he added. The findings could change the existing understanding of schizophrenia and raise the possibility that testing people at risk for the condition could enable them to undergo treatment early enough to prevent the most severe symptoms, based on the researchers.